Reach Us +44-7482-864460
Association Between Plasminogen Activator Inhibitor-1-675 4g/5g Insertion/deletion Polymorphism And Chronic Obstructive Pulmonary Disease | 86560
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Share This Page

Association between plasminogen activator inhibitor-1-675 4g/5g insertion/deletion polymorphism and chronic obstructive pulmonary disease

Joint Event on 10th International Conference on Genomics and Molecular Biology & 6th International Conference on Integrative Biology

Rabab El Wahsh

Menoufia University, Egypt

Posters & Accepted Abstracts: J Mol Genet Med

DOI: 10.4172/1747-0862-C2-028

Molecular pathology of chronic obstructive pulmonary disease (COPD) is still being investigated to discover relationships with disease pathogenesis. Evidence of plasminogen activator inhibitor-1 (PAI-1) overexpression in the sputum and the blood of COPD patients is growing. We aimed to investigate the potential relation between PAI-1 promoter 4G/5G insertion/ deletion polymorphism and COPD development. In a case-control study, we genotyped 117 COPD patients and 160 control subjects for PAI-1 promoter 4G/5G polymorphism by an allele-specific polymerase chain reaction analysis. All subjects were male smokers. In the co-dominant model, there was a significant difference in the distribution of 5G/5G, 4G/5G and 4G/4G genotypes between COPD patients and controls (p=0.002). In the recessive model, carriers of 4G/4G genotype were significantly higher in COPD patients than controls (p=0.01). Carriers of 4G/4G genotype were at higher risk to develop COPD than those carrying 5G/5G or 4G/5G genotypes (crude odds ratio (OR)=2.10, 95% confidence interval (CI)=1.19-3.73, adjusted OR=2.5, 95% CI=1.22-3.99). PAI-1 4G/5G genetic variations are associated with COPD development in males. [email protected]